Canadian guidelines for insomnia — what CADTH, Health Canada, and Canadian clinicians recommend

What Canadian guidelines say about insomnia

Insomnia is the most common sleep disorder in Canada, affecting an estimated 13% of Canadians with chronic symptoms (3+ nights per week for 3+ months) and a far larger proportion experiencing occasional or short-term insomnia. Note that seasonal affective disorder (SAD) causes a distinct sleep pattern — hypersomnia rather than insomnia — and has its own diagnostic and treatment pathway. Canadian clinical bodies — including the Canadian Sleep Society (CSS), the College of Family Physicians of Canada (CFPC), and CADTH — have each published guidance or evidence reviews that inform how Canadian clinicians should treat it.

The consistent message across all major Canadian guidelines is that Cognitive Behavioural Therapy for Insomnia (CBT-I) is the recommended first-line treatment for chronic insomnia. Pharmacotherapy is positioned as a short-term adjunct or second-line option, not a primary treatment. This aligns with international guidelines from the American Academy of Sleep Medicine and European Sleep Research Society but applies specifically within Canada's healthcare and regulatory context.

Primary sources for Canadian insomnia guidelines

Canada does not have a single named clinical practice guideline document for insomnia. Instead, Canadian clinicians follow a converging set of evidence reviews, clinical recommendations, and prescribing standards. These are the primary sources we summarise on this page:

International alignment: Canadian recommendations sit alongside guidance from the American Academy of Sleep Medicine (AASM), the European Sleep Research Society (ESRS), and the British Association for Psychopharmacology — all of which identify CBT-I as the first-line treatment for chronic insomnia.

GoToSleep.ca summarises publicly available guidance. This page is not medical advice — always consult your physician for treatment decisions.

CADTH insomnia review: CBT-I recommended as first-line treatment in Canada

CADTH insomnia evidence reviews recommend Cognitive Behavioural Therapy for Insomnia (CBT-I) as the first-line treatment for chronic insomnia in Canada. Pharmacotherapy is a short-term adjunct or second-line option only.

CADTH (the Canadian Drug and Technologies in Health agency — now part of the broader Canadian health technology assessment framework) has published systematic reviews and rapid evidence reports on insomnia treatment. Key findings from CADTH insomnia reviews:

• CBT-I produces durable outcomes: CADTH evidence reviews note that CBT-I benefits persist at 12- and 24-month follow-up, unlike pharmacotherapy whose effects are tied to continued use.
• Pharmacotherapy is appropriate short-term: For acute insomnia (less than 4 weeks), short-term use of sleep medication may be appropriate as a bridge while CBT-I is initiated or accessed.
• Z-drugs carry dependency risk: CADTH reviews highlight the dependency, tolerance, and rebound insomnia risks of z-drugs (zopiclone, zolpidem) and benzodiazepines, supporting guideline recommendations to limit their duration.
• Digital CBT-I is effective: CADTH has reviewed digital health technologies and found app-based and internet-delivered CBT-I programs clinically comparable to therapist-delivered treatment, improving access in underserved regions of Canada.

Acute vs chronic insomnia — Canadian definitions and treatment

Canadian guidelines treat acute and chronic insomnia differently. The distinction matters because it determines whether short-term hypnotic use is appropriate or whether CBT-I should be the primary intervention.

• Acute insomnia: symptoms lasting less than 3 months, typically triggered by an identifiable stressor (bereavement, illness, schedule disruption, acute anxiety). Most cases resolve naturally once the stressor passes. A short course of a z-drug (zopiclone) or low-dose melatonin may be appropriate as a bridge. CBT-I principles — stimulus control and sleep restriction in particular — can and should be introduced early.
• Chronic insomnia: difficulty initiating or maintaining sleep 3 or more nights per week for 3 or more months, with daytime impairment. CBT-I is the recommended first-line treatment per CADTH, the Canadian Sleep Society, and Choosing Wisely Canada. Pharmacotherapy is not recommended as a first-line or long-term treatment for chronic insomnia.

Treatment of acute insomnia should be reassessed within 4 weeks. If symptoms persist beyond 4 weeks, the clinical approach shifts toward chronic insomnia management and CBT-I should be initiated or referred.

Canadian guidelines for insomnia and benzodiazepines

Canadian guidelines do not recommend benzodiazepines (lorazepam, temazepam, clonazepam, triazolam) as first-line treatment for chronic insomnia. This is the consistent position across CADTH evidence reviews, the College of Family Physicians of Canada's Choosing Wisely Canada items, the Canadian Geriatrics Society, and provincial prescribing regulators including the CPSO.

Choosing Wisely Canada — direct recommendations

• CFPC (Family Medicine): "Don't routinely prescribe benzodiazepines as first-line treatment for insomnia, agitation, or delirium in older adults" — Choosing Wisely Canada list item.
• Canadian Geriatrics Society: "Don't use benzodiazepines or other sedative-hypnotics in older adults as first choice for insomnia" — citing fall risk, cognitive impairment, and dependency.
• Ontario College of Pharmacists: pharmacists are encouraged to initiate conversations about CBT-I alternatives when filling prescriptions for benzodiazepines or z-drugs for insomnia.

Beers Criteria and Canadian geriatric practice

Canadian geriatricians widely apply the Beers Criteria, which lists benzodiazepines as potentially inappropriate medications for older adults. Long-acting agents (diazepam, clonazepam) carry the highest risk; short-acting agents (lorazepam, temazepam) are less risky but still preferentially avoided for chronic insomnia.

Z-drugs (zopiclone, zolpidem)

Z-drugs are pharmacologically distinct from benzodiazepines but share many of the same risks: dependency, rebound insomnia, next-day cognitive and motor impairment. Health Canada has issued specific warnings about next-day driving impairment associated with zopiclone. CADTH evidence reviews and Canadian Sleep Society recommendations both advise limiting z-drug use to the shortest effective duration with periodic reassessment — typically not exceeding 4 weeks without re-evaluation.

CPSO prescribing standard

The College of Physicians and Surgeons of Ontario's prescribing standard for benzodiazepines and z-drugs requires that prescribers document the indication, plan for duration, and review of safer alternatives including CBT-I. Other provincial regulators (CPSBC in BC, CPSA in Alberta) have similar expectations.

Insomnia guidelines for elderly Canadians

Canadian insomnia guidelines treat older adults (commonly defined as 65+) as a distinct group because the risk-benefit calculus of sleep medication shifts dramatically with age. Fall-related hip fractures, cognitive impairment, polypharmacy interactions, and dependency are all more common and more consequential in this population.

What Canadian guidelines specifically recommend for elderly

• CBT-I is first-line, including for older adults. Evidence supports its effectiveness past age 65, though some protocols are adapted for cognitive flexibility and the natural reduction in sleep depth that occurs with normal ageing.
• Avoid benzodiazepines and z-drugs as first-line — explicit Choosing Wisely Canada recommendations from both the Canadian Geriatrics Society and the College of Family Physicians of Canada.
• Beers Criteria classifies benzodiazepines as potentially inappropriate medications for older adults regardless of indication; widely applied in Canadian geriatric practice.
• Antihistamine-based OTC sleep aids (diphenhydramine, doxylamine): also on the Beers Criteria — anticholinergic burden, next-day cognitive impairment, fall risk. Not recommended for older adults.
• Melatonin: Health Canada approves 0.5–10 mg for adults; in older adults a lower starting dose (0.3–1 mg) is commonly used given evidence of declining endogenous melatonin production with age. There is some evidence for prolonged-release melatonin in this group.

CBT-I adaptations for older adults

CBT-I in older adults requires modest adaptation. Sleep restriction protocols may use a slightly larger sleep window to account for reduced sleep efficiency that is normal at older ages. Cognitive components address common age-related beliefs ("I need 8 hours like I did when I was 30"). The core techniques — stimulus control, sleep restriction, cognitive restructuring, and relaxation training — remain effective. Group CBT-I in community settings has been used successfully in Canadian senior centres and is sometimes offered through provincial mental health programs.

Deprescribing long-term hypnotics in seniors

Many older Canadians have been on benzodiazepines or z-drugs for years, often started during a stressful period and never reviewed. The Bruyère Research Institute Deprescribing Network — a Canadian-developed evidence-based deprescribing initiative — provides specific guidelines for tapering benzodiazepines and z-drugs in seniors. The protocol typically involves gradual dose reduction over weeks to months, paired with CBT-I support. Provincial pharmacy programs in Ontario and Quebec have launched specific senior deprescribing initiatives aligned with this framework.

Health Canada approved treatments for insomnia

Health Canada regulates insomnia treatments across two streams: Natural Health Products (NHPs) and prescription or over-the-counter drugs.

Natural Health Products (NHPs)

Melatonin is the most significant NHP for insomnia in Canada. Unlike the US (where it is an unregulated supplement), Canadian melatonin products must carry an NPN (Natural Product Number) issued by Health Canada after pre-market review of safety, efficacy, and quality. Health Canada-approved melatonin indications include: sleep-onset insomnia, jet lag, and shift work sleep disorder. The approved dose range is 0.5–10 mg, with Health Canada guidance noting that lower doses (0.5–1 mg) are as effective as higher doses for most adults. For NPN verification, brand picks, and the "melatonin Canada banned" myth, see our full Melatonin Canada NPN guide. Other NHP sleep aids — valerian, L-theanine, magnesium glycinate — may be sold with NPNs but with more limited efficacy claims.

Prescription sleep medications

Zopiclone (a z-drug) is the most commonly prescribed sleep medication in Canada and is only available by prescription. Benzodiazepines (temazepam, triazolam) are also prescribed but carry higher dependency risk. Health Canada has issued warnings on z-drugs regarding next-day impairment, particularly for driving, and recommends limiting use to the shortest effective duration.

OTC sleep aids

Diphenhydramine-based OTC sleep aids (Benadryl, ZzzQuil) are approved by Health Canada for occasional sleeplessness. Health Canada does not recommend these for chronic insomnia — tolerance develops within days, and antihistamine effects impair cognitive function the following day. They are not part of evidence-based insomnia treatment guidelines.

Canadian clinical practice guidelines

Several Canadian professional bodies have published or endorsed insomnia treatment guidelines:

• Canadian Sleep Society (CSS): The CSS endorses CBT-I as first-line treatment and has advocated for better access to trained CBT-I providers across Canada. The CSS also recognises that the therapist shortage requires digital CBT-I as a practical alternative.
• College of Family Physicians of Canada (CFPC): The CFPC's Choosing Wisely Canada campaign specifically recommends against prescribing sleep medication as first-line treatment for insomnia, and against routinely renewing sleep medication prescriptions without reassessment and discussion of CBT-I.
• Canadian Psychiatric Association (CPA): CPA guidelines for insomnia comorbid with anxiety and depression recommend addressing the insomnia directly with CBT-I rather than assuming it will resolve when the mental health condition is treated.
• Choosing Wisely Canada: This national initiative — endorsed by 40+ Canadian medical societies — includes specific recommendations against using benzodiazepines or z-drugs for insomnia in older adults, citing fall risk, cognitive impairment, and dependency.

Finding insomnia treatment in Canada

The largest practical barrier for Canadians is accessing CBT-I despite guidelines recommending it. Here are the routes available:

• Ask your GP for a sleep clinic referral — sleep medicine clinics at major Canadian hospitals offer CBT-I; wait times vary by province
• Extended health benefits — if your employer plan covers registered psychologists, CBT-I delivered by a psychologist trained in sleep qualifies
• Digital CBT-I programs — Sleepio, Somryst (Health Canada cleared), and the free Insomnia Coach app deliver evidence-based CBT-I without waitlists
• Provincial mental health programs — several provinces offer subsidised psychological therapy that can include CBT-I

For a full breakdown including city-by-city options, see our CBT-I treatment guide for Canadians →

Clinical practice guideline for insomnia in Ontario

Ontario has specific infrastructure for accessing insomnia treatment that differs from other provinces. For Ontarians seeking CBT-I or clinical insomnia care:

• CAMH (Centre for Addiction and Mental Health): CAMH in Toronto offers sleep medicine assessment and CBT-I through its Mood and Anxiety Program. Referral through a family physician is typically required.
• Ontario Sleep Clinics: Hospital-based sleep clinics at Sunnybrook, Toronto General, and Ottawa Hospital provide polysomnography and CBT-I programs. OHIP covers the assessment; CBT-I delivery varies by clinic.
• ConnexOntario: Call 1-866-531-2600 to find provincially funded mental health programs, including those offering CBT for insomnia comorbid with anxiety or depression.
• Employer extended health: Ontario's extended health plans frequently cover registered psychologist visits, which can include CBT-I. Confirm "insomnia" or "sleep disorders" is a covered presenting complaint with your insurer.
• Ontario Drug Benefit (ODB): For insomnia medication, zopiclone is covered under ODB for eligible Ontarians. However, Ontario pharmacists are encouraged to initiate conversations about CBT-I as an alternative when presenting prescriptions for z-drugs — consistent with the Choosing Wisely Canada guidance endorsed by the Ontario College of Pharmacists.

There is no single Ontario-specific insomnia clinical practice guideline document separate from the national framework. Ontario clinicians follow CADTH evidence reviews, Canadian Sleep Society recommendations, and the College of Physicians and Surgeons of Ontario's prescribing guidance on benzodiazepines and z-drugs, which limits duration and requires periodic reassessment.

Frequently asked questions